# China NMPA Drug Inspection - Hubei Daodi Medicinal Herbs Technology Co., Ltd. - safflower

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hubei-daodi-medicinal-herbs-technology-co-ltd/002837bb-b428-4b2a-9eca-25f9db0f14c0/
Source feed: China

> China NMPA drug inspection for Hubei Daodi Medicinal Herbs Technology Co., Ltd. published February 09, 2018. Drug: safflower. On February 9, 2018, the Henan Provincial Food and Drug Administration announced findings regarding four batches of subs

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from the Henan Provincial Food and Drug Administration regarding four batches of substandard drugs (Issue No. 2, 2018)
- Company Name: Hubei Daodi Medicinal Herbs Technology Co., Ltd.
- Publication Date: 2018-02-09
- Drug Name: safflower
- Inspection Finding: Impurities do not meet the requirements
- Action Taken: Relevant food and drug regulatory authorities have taken necessary risk control measures such as sealing up, seizing, and suspending the sale of substandard drugs, and have investigated and dealt with the source units of the samples in accordance with the law.
- Summary: On February 9, 2018, the Henan Provincial Food and Drug Administration announced findings regarding four batches of substandard drugs from various manufacturers in China. This regulatory action followed tests conducted by several local drug inspection agencies, with the Chinese Pharmacopoeia 2015 Edition, Part I, serving as the primary regulatory framework for assessing product quality. The identified deficiencies pertained to specific quality attributes for traditional Chinese medicine products. Bozhou Jingwan Traditional Chinese Medicine Pieces Factory's Wujiapi (五加皮) was found to have substandard extractives. Anhui Yiyuantang Traditional Chinese Medicine Pieces Technology Co., Ltd. produced stir-fried Atractylodes lancea with non-compliant moisture and content levels. Hubei Daodi Medicinal Materials Technology Co., Ltd.'s safflower product exceeded impurity limits. Lastly, Chongqing Grelin Pharmaceutical Co., Ltd.'s Ginseng and Atractylodes Macrocephala Powder was found to contain excessive moisture. In response, the Henan Provincial Food and Drug Administration mandated immediate risk control measures. These included sealing, seizing, and suspending sales of the identified substandard drugs. Regulatory departments were further instructed to investigate and legally penalize the entities responsible for distributing these non-compliant products to ensure public safety and adherence to quality standards.

Company: https://www.globalkeysolutions.net/companies/hubei-daodi-medicinal-herbs-technology-co-ltd/7fc8ef0a-14b2-4d1b-aae9-ee87f5ff5147/